Skip to main content
SpringerLink
Log in
Book cover

Surviving Intensive Care pp 221–234Cite as

How should we Measure the Economic Consequences of Critical Illness?

  • Conference paper

Part of the book series: Update in Intensive Care Medicine ((UICMSOFT,volume 39))

Abstract

Florence Nightingale, surrounded by wounded soldiers, had only limited time, and choices had to be made about who to treat, how intensely to treat them, and for how long. It was a war, she was with few, and she became a hero. Health care in western societies is much more sophisticated, there are no domestic wars, doctors and nurses are with many, and they rarely become heroes. However, the need to make choices has not changed. Choices are made at all levels of health care; they are made at the governmental level when considering, for example, vaccination programs, and they are made at the level of doctor and patient when considering the best treatment.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Classer JH, Chrzanowski RS (1988) Medical Technology Assessment, appropriate methods, valuable answers Health Policy 3267–276

    Article  Google Scholar 

  2. Drummond, B O’Brien, GL Stoddart, GW Torrance (1997) Methods for the Economic Evaluation of Health Care Programmes, 2nd Edition Oxford Medical Publications, Oxford

    Google Scholar 

  3. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in Health and Medicine Oxford University Press, New York

    Google Scholar 

  4. Ontario Ministry of Health (1994) Ontario Guidelines for Economic Analysis of Pharmaceutical Products Ontario Ministry of Health, Toronto

    Google Scholar 

  5. Commonwealth department of human services and health (1995) Guidelines for the Pharmaceutical industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee including major submissions involving economic analyses Australian Government Publishing Service, Canberra

    Google Scholar 

  6. Black WC (1990) The CE plane — A graphic representation of cost-effectiveness, Med Decis Making 10212–214

    Article  PubMed  CAS  Google Scholar 

  7. Mansley EC, McKenna MT (2001) Importance of perspective in economic analyses of cancer screening decisions, Lancet 3581169–1173

    Article  PubMed  CAS  Google Scholar 

  8. Serruys PW, Unger F, Sousa JE, et al (2001) Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease N Engl J Med 3441117–1124

    Article  PubMed  CAS  Google Scholar 

  9. Serruys PW, Van Hout B, Bonnier B, et al (1998) Randomised comparison of implantation of heparin-coated stent with balloon angioplasty in selected patients with coronary artery disease (Benestent II) The Lancet 352673–681

    Article  CAS  Google Scholar 

  10. Vincent JL, Moreno R, Takala J et al (1996) The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure Intensive Care Med 7707–710

    Article  Google Scholar 

  11. Zwart-van Rijkom JEF, van Hout BA (2001) Cost-efficacy in interventional cardiology; results from the EPISTENT study Eur Heart J 221476–1484

    Article  PubMed  CAS  Google Scholar 

  12. Buxton, MJ, Drummond MF, Van Hout BA, et al (1997) Modeling in economic evaluation: an unavoidable fact of life Health Econ 6217–227

    Article  PubMed  CAS  Google Scholar 

  13. Bernard GR, Vincent JL, Laterre PF, et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 344699–709

    Article  PubMed  CAS  Google Scholar 

  14. Quartin AA, Schein RM, Kett DH, et al (1997) Magnitude and duration of the effect of sepsis on survival JAMA 2771058–1063

    Article  PubMed  CAS  Google Scholar 

  15. Koopmanschap MA, Rutten FFH, Van Ineveld BM, Van Roijen L (1995) The friction cost method for measuring indirect costs of disease J Health Econ 14171–189

    Article  PubMed  CAS  Google Scholar 

  16. Payers PM, Machn D (2000) Quality of Life, Assessment, Analysis and Interpretation John Wiley and Sons, Chichester

    Google Scholar 

  17. Bowling A (1995) Measuring Disease, a Review of Life Measurement Scales Open University Press, Philadelphia

    Google Scholar 

  18. Dolan P (1997) Modeling valuations for EuroQol health states Med Care 351095–1108

    Article  PubMed  CAS  Google Scholar 

  19. Feeny D, Furlong W, Torrance GW, et al (2002) Multiattribute and single-attribute utility functions for the health utilities index mark 3 system Med Care 40113–128

    Article  PubMed  Google Scholar 

  20. Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36 J Health Econ 21271–292

    Article  PubMed  Google Scholar 

  21. Van Hout BA, Al M, Gordon GS, Rutten FFH (1994) Costs, effects and C/E-ratio’s alongside a clinical trial Health Econ 3309–319

    Article  PubMed  Google Scholar 

  22. Briggs AH, WonderUng DE, Mooney CZ (1997) Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation Health Econ 6327–340

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, PO Box 86060, 3508 AB, Utrecht, The Netherlands

    B.A. van Hout (Professor of Medical Technology Assessment)

  2. Dept of Critical Care Medicine, University of Pittsburgh, 604 Scaife Hall 200 Lothrop Street, Pittsburgh, PA, 15213, USA

    D.C. Angus (Associate Professor)

Authors
  1. B.A. van Hout
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D.C. Angus
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Critical Care Medicine, University of Pittsburgh, 3550 Terrace Street, Pittsburgh, PA, 15261, USA

    Derek C. Angus MD, MPH, FCCM, FCCP (Associate Professor and Vice Chair for Research) (Associate Professor and Vice Chair for Research)

  2. Anaesthesiology and Emergency Department, Fondation Hôpital St Joseph, 185 rue Raymond Losserand, 75674, Paris Cedex 14, France

    Jean Carlet MD (Head of the Intensive Care Unit Coordinator of the Intensive Care) (Head of the Intensive Care Unit Coordinator of the Intensive Care)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

van Hout, B., Angus, D. (2003). How should we Measure the Economic Consequences of Critical Illness?. In: Angus, D.C., Carlet, J. (eds) Surviving Intensive Care. Update in Intensive Care Medicine, vol 39. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55733-0_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-55733-0_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-44149-6

  • Online ISBN: 978-3-642-55733-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation